Specify a stock or a cryptocurrency in the search bar to get a summary
Biomind Labs Inc
BMNDBiomind Labs Inc., a biotech research and development company, focuses on developing novel pharmaceutical drugs and nanotech delivery systems for various psychiatric and neurological conditions. The company is developing BMND01, which is in Phase II clinical trials for use in the treatment of depression; and BMND08, a 5-Methoxy-N,N-dimethyltryptamine based candidate that is in Phase II clinical trials for treatment of depression and anxiety in patients with Alzheimer's-type cognitive impairment. It is also developing new and preclinical drug candidates, including BMND02 for treating fibromyalgia, BMND03 for treating addictive disorders, BMND05 for treating chronic pain, BMND06 for treating inflammatory disorders, and BMND07 for treating major depressive disorder. The company is headquartered in Canelones, Uruguay. Address: Building Ceibo Of. 002, Canelones, Uruguay
Analytics
WallStreet Target Price
–P/E ratio
–Dividend Yield
–Current Year
Last Year
Current Quarter
Last Quarter
Current Year
Last Year
Current Quarter
Last Quarter
Key Figures BMND
Dividend Analytics BMND
Dividend growth over 5 years
–Continuous growth
–Payout Ratio 5 years average
–Dividend History BMND
Stock Valuation BMND
Financials BMND
Results | 2019 | Dynamics |